This study describes late bowel morbidity prospectively assessed in the multi-institutional EMBRACE study on MRI-guided adaptive brachytherapy in locally advanced cervical cancer (LACC).
A total of 1176 patients were analyzed. Physician reported morbidity (CTCAE v.3.0) and patient reported outcome (PRO) (EORTC QLQ C30/CX24) were assessed at baseline and at regular follow-up.
At 3/5 years the actuarial incidence of bowel morbidity grade 3–4 was 5.0%/5.9%, including incidence of stenosis/stricture/fistula of 2.0%/2.6%. Grade 1–2 morbidity was pronounced with prevalence rates of 28–33% during follow-up. Diarrhea and flatulence were most frequently reported, significantly increased after 3 months and remained elevated during follow-up. Incontinence gradually worsened with time. PRO revealed high prevalence rates. Diarrhea ≥“a little” increased from 26% to 37% at baseline to 3 months and remained elevated, difficulty in controlling bowel increased from 11% to 26% at baseline to 3 months gradually worsening with time. Constipation and abdominal cramps improved after treatment.
Bowel morbidity reported in this large cohort of LACC patients was limited regarding severe/life-threatening events. Mild-moderate diarrhea, flatulence and incontinence were prevalent after treatment with PROs indicating a considerable and clinically relevant burden. Critical knowledge based on the extent and manifestation pattern of treatment-related morbidity will serve future patient management.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Radiotherapy and Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.Radiother Oncol. 2011; 100: 116-123
- MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a nordic perspective.Acta Oncol. 2013; 52: 1510-1519
- Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.Radiother Oncol. 2016; 120: 428-433
- Image guided adaptive brachytherapy in cervix cancer: a new paradigm changing clinical practice and outcome.Radiother Oncol. 2016; 120: 365-369
- Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: a mono-institutional experience.Acta Oncol. 2015; 54: 1558-1566
- Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study.Radiother Oncol. 2012; 103: 305-313
- Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience.Radiother Oncol. 2013; 107: 69-74
- Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy.Gynecol Oncol. 2014; 135: 231-238
EMBRACE (An international study on MRI-guided brachytherapy in locally advanced cervical cancer). <https://www.embracestudy.dk/>.
- Long-term survival and late toxicity after chemoradiotherapy for cervical cancer – The Addenbrooke’s experience.Clin Oncol. 2008; 20: 358-364
- Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy.Radiother Oncol. 1997; 42: 143-153
- Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis.Int J Radiat Oncol Biol Phys. 2012; 84: 973-982
- Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists’ Audit.Clin Oncol. 2010; 22: 590-601
- Prevention and management of radiation-induced late gastrointestinal toxicity.Clin Oncol (R Coll Radiol). 2015; 27: 656-667
- Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the embrace study.Int J Radiat Oncol Biol Phys. 2014; 89: 88-95
- Late complications from chemoradiotherapy for cervical cancer: reflections from cervical cancer survivors 10 years after the National Cancer Institute Alert.Clin Oncol. 2010; 22: 588-589
- Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency.Int J Radiat Oncol. 2007; 69: 1218-1221
- Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician’s attention.Qual Life Res. 2013; 22: 2685-2691
- Can patient-reported outcome measures identify cancer patients’ most bothersome issues?.J Clin Oncol. 2011; 29: 1216-1220
- Patient-reported outcomes and the evolution of adverse event reporting in oncology.J Clin Oncol. 2007; 25: 5121-5127
- Pelvic radiation disease.Color Dis. 2015; 17: 2-6
- Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicentre EMBRACE study.Radiother Oncol. 2016; 120: 412-419
- Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.Radiother Oncol. 2005; 74: 235-245
- Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy – 3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.Radiother Oncol. 2006; 78: 67-77
- Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery – a mono-institutional prospective study.Gynecol Oncol. 2015; 136: 415-423
- Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients.Strahlenther Onkol. 2012; 188: 933-939
- Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population.Eur J Cancer. 2011; 47: 667-675
- Health-related quality of life in locally advanced cervical cancer patients after definitive chemoradiation therapy including image guided adaptive brachytherapy: an analysis from the EMBRACE study.Int J Radiat Oncol Biol Phys. 2016; 94: 1088-1098
- The impact of radiotherapy late effects on quality of life in gynaecological cancer patients.Br J Cancer. 2009; 100: 1558-1565
- The patients’ perspective on physical symptoms after radiotherapy for cervical cancer.Gynecol Oncol. 2000; 76: 14-23
- The imperative for a new approach to toxicity analysis in oncology clinical trials.J Natl Cancer Inst. 2015; 107: 1
- Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix.Int J Radiat Oncol Biol Phys. 1995; 32: 1289-1300
- Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group Trial (RTOG) 90–01.J Clin Oncol. 2004; 22: 872-880
- Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.Gynecol Oncol. 2015; 139: 288-294
- Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians’ assessments agree with those of their patients?.Int J Radiat Oncol Biol Phys. 2008; 71: 1335-1342
- Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.J Clin Oncol. 2015; 33: 910-915
- Validity and reliability of the U.S. National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).JAMA Oncol. 2015; 1: 1051-1059
- The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.Clin Transl Radiat Oncol. 2018; 9: 48-60
- Radiation-induced small bowel disease: latest developments and clinical guidance.Ther Adv Chronic Dis. 2014; 5: 15-29
- Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer.Acta Oncol. 2015; 54: 1326-1334
- Correlation of dose–volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy.Radiother Oncol. 2009; 91: 173-180
- Overview faecal incontinence: a late side-effect of pelvic radiotherapy.YCLON. 2005; 17: 469-477
- Guidance: the practical management of the gastrointestinal symptoms of pelvic radiation disease.Frontline Gastroenterol. 2015; 6: 53-72
- Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial.Lancet. 2013; 382: 2084-2092
Published online: June 04, 2018
Accepted: May 17, 2018
Received in revised form: May 17, 2018
Received: August 4, 2017
© 2018 Elsevier B.V. All rights reserved.